pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior segment uveitis showing that intravitreal Durasert significantly reduced the recurrence of uveitis in the study eye at 12 months vs. sham injection (36.6% v. 71.2%, p<0.001). Durasert is a three-year sustained-release fluocinolone acetonide treatment.

In June 2017, pSivida reported that Durasert met the primary endpoint of reducing the recurrence of uveitis in the study eye at six months vs. sham injection (21.8% vs. 53.8%, p<0.001). The trial's secondary endpoint is recurrence of uveitis in the study eye at three years...